학술논문

24P Is molecular characterization useful for targeted therapy orientation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) included in early phase clinical trials?
Document Type
Abstract
Source
In Annals of Oncology October 2020 31 Supplement 5:S1224-S1224
Subject
Language
ISSN
0923-7534